CANTARGIA AB
556791-6019ActiveDeveloping antibody-based drugs targeting IL1RAP for serious diseases.
Översikt
- 20–49
- Anställda
- ≤1t SEK
- Omsättning
- 2009
- Grundat
Nyckelbeslutsfattare
Hilde H. Steineger
CEO
Wolfram Dempke
Chief Medical Officer
Magnus Persson
Chairman of the Board
Damian Marron
Board Member
+6 fler kontakter i Funnelfeedr
Beskrivning
Cantargia is a biotechnology company focused on developing innovative antibody-based therapeutics. Their primary scientific target is the protein IL1RAP, which plays a role in several serious conditions. The company's mission is to create treatments for cancer as well as autoimmune and inflammatory...
Taggar
Nyckelord
Teknikstack
Företagsinformation
- Bransch
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE556791601901
Beslutsfattare
10 kontakter i FunnelfeedrHilde H. Steineger
CEO
Wolfram Dempke
Chief Medical Officer
Magnus Persson
Chairman of the Board
Damian Marron
Board Member
Patrik Renblad
CFO
Flavia Borellini
Board Member
Ton Berkien
CBO
David Liberg
CSO
Jenny Sundqvist
Board Member
Anders Martin-Löf
Board Member
Liknande företag
20 liknande företag i FunnelfeedrHamlet BioPharma AB
5–9 anställdaInnovative pharmaceutical company developing targeted cancer and infection treatments.
Alligator Bioscience AB
10–19 anställdaClinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
Beactica Therapeutics AB
5 anställdaPrecision medicine company developing novel therapeutics via targeted protein degradation.
BioGaia Pharma AB
0 anställdaDeveloping and out-licensing novel biotherapeutic platforms from microbiome research.
Nanohumps Biosciences Oy
Pioneering revolutionary cancer therapies using proprietary nanosized antibodies.
Utforska mer
Frågor om CANTARGIA AB
Vill du se Funnelfeedr i praktiken?
Boka en gratis demo och upptäck hur Funnelfeedr hjälper dig att hitta och konvertera dina idealkunder.
Boka en demo